A Wild-Type Gut Bacterium Cut Colitis Inflammation in Mice. Here’s What It Did.

Ulcerative colitis has no cure, and the treatments that exist, from anti-inflammatory drugs to biologics, work inconsistently and carry real side-effect burdens. That gap keeps researchers hunting for alternatives, including probiotic strains that might calm the gut's immune response before it spirals. A new study published in NFS Journal reports that a wild-type strain called Pediococcus acidilactici SK2, isolated from the human gastrointestinal tract, reduced inflammatory markers and helped preserve microbial diversity in a mouse model of colitis. The findings are early and preliminary, but they add a specific mechanistic story to what has mostly been anecdotal territory.

P. acidilactici SK2 Lowered Key Inflammatory Cytokines in Colitic Mice

Mice pretreated with 10^9 CFU of P. acidilactici SK2 daily for three days, then subjected to five days of dextran sulfate sodium (DSS) in their drinking water, showed noticeably different inflammatory profiles than untreated colitic controls. DSS is a chemical irritant that strips the colon lining and triggers an immune response closely resembling human ulcerative colitis; it is one of the most widely used and reproducible preclinical colitis models available.

In DSS-treated mice given SK2, mRNA expression of the pro-inflammatory cytokines Il-1β and Il-6 dropped relative to DSS-only animals. Two chemokines that recruit neutrophils and macrophages to the site of inflammation, Cxcl2 and Ccl3, were also reduced. At the protein level, these shifts held up. The anti-inflammatory cytokine Il-10 moved in the same direction as the inflammatory signals, but the difference between the two DSS groups did not reach statistical significance, a detail worth noting.

Beyond cytokines, SK2-treated mice showed elevated expression of Ocln (occludin) and Muc2, genes encoding a tight junction protein and a mucus layer component respectively. Both are typically suppressed during colitis, and their reduction is thought to worsen barrier permeability and bacterial translocation. Restoring their expression suggests the strain may help shore up the epithelial barrier, though histological confirmation of goblet cell and epithelial changes was not part of this study.

Ulcerative Colitis Affects Millions and Lacks Good Long-Term Options

The urgency behind probiotic research for colitis comes partly from the scale of the problem. Rising IBD prevalence and costs in the United States alone put the number of people living with inflammatory bowel disease somewhere between 2.4 and 3.1 million, with annual healthcare costs reaching roughly $8.5 billion as of 2018. Globally, incidence is climbing in regions where it was once rare, straining health systems that were not built for chronic, relapsing gut disease.

Existing therapies, including aminosalicylates, corticosteroids, and biologics targeting TNF or integrin pathways, achieve remission for many patients but not all, and long-term use carries risks ranging from immunosuppression to infusion reactions. Probiotics have attracted interest precisely because they might act upstream of the inflammatory cascade, at the level of the microbiome, without the systemic exposure that pharmacological agents require. But probiotic therapy carries its own limitations, including variable efficacy across strains and individuals, and theoretical risks that have kept regulatory agencies cautious.

How the DSS Mouse Model and 16S Sequencing Revealed SK2's Microbiome Effects

The research team paired the standard DSS colitis protocol with 16S rRNA sequencing of fecal samples to track how the gut microbial community shifted across groups. This combination, chemical injury plus community-level genomic profiling, let the team go beyond symptom scores and look directly at the ecological consequences of probiotic pretreatment.

Before DSS exposure, SK2-pretreated mice already showed greater species richness (measured by OTU counts) than untreated controls. After DSS, both groups lost microbial diversity, as measured by Richness and Shannon indexes, but the SK2 group lost less effective diversity, suggesting a partial buffering effect. Beta diversity analysis, which compares the overall composition of communities rather than just counts, revealed that SK2 mice clustered distinctly from DSS-only mice, meaning the strain reshaped the community structure in ways that persisted even under inflammatory stress.

At the genus level, several taxa that DSS typically suppresses, including Allobaculum, Dubosiella, and Bifidobacterium, remained at higher abundance in the SK2-treated group. Ileibacterium valens, a species with 100% sequence similarity to one of the detected OTUs, was sharply reduced by DSS in untreated mice but largely restored in SK2-treated animals. Other Pediococcus acidilactici strains have shown similar capacity to modulate gut microbiota composition and reduce inflammation across different disease contexts, which gives this genus a coherent track record even if strain-level effects vary considerably.

What This Study Cannot Yet Tell Us

The authors are transparent about the gaps. The study used an acute DSS model: five days of chemical exposure is not the same as the years-long, relapsing-remitting course of human ulcerative colitis. Chronic colitis models, which use repeated DSS cycles and can induce fibrosis, would test whether SK2's effects hold over longer exposures.

The paper also did not include histological examination of colon tissue, which would clarify whether goblet cell numbers and epithelial architecture actually improved or whether the gene expression changes reflect compensatory signaling without structural rescue. The mechanisms driving SK2's effects remain uncharacterized: the study did not test heat-killed bacteria, cell-free supernatants, or microbial metabolites, so it is not yet possible to say whether live colonization is necessary or whether a secreted compound does the work. Earlier research on a related strain found that oral Pediococcus acidilactici modulated indigenous gut microbiota and boosted bacteria with anti-inflammatory properties in a food allergy model, pointing to the gut community as a likely mediator, but the specific pathway for SK2 remains to be traced.

Next Steps Before SK2 Could Reach Clinical Testing

The authors flag several concrete priorities. Comparative experiments using heat-killed SK2, filtered culture supernatants, and metabolomic profiling of microbial byproducts would help isolate which component of the live bacterium drives the observed effects. Histological analysis of colon sections is described as a necessary follow-up. Chronic colitis protocols would test durability.

Beyond bench work, any path toward human use requires preclinical safety data and eventually controlled trials. Probiotic research has a long history of animal results that do not replicate in human guts, which are more diverse, less controlled, and already colonized by trillions of competing microbes. SK2's origin, isolated from the human GI tract rather than from food fermentation, may give it some colonization advantage, but that remains speculative at this stage. For now, P. acidilactici SK2 is a mechanistically interesting candidate that has earned a more rigorous preclinical look.

Evidence rating

INVESTIGATIONAL — 71/100

Caveats:

• This study was conducted entirely in mice; results may not translate to humans.
• No histological analysis of colon tissue was performed, limiting conclusions about structural gut damage.
• The mechanisms by which P. acidilactici SK2 exerts its effects were not directly identified in this study.
• Funding source was not disclosed by the authors.

Preclinical mouse study using a DSS-induced colitis model. Demonstrates associations between P. acidilactici SK2 supplementation and reduced inflammatory markers, improved barrier gene expression, and preserved microbial diversity, but cannot establish causation in humans and has not been replicated in clinical populations. No histological data were reported, and the precise mechanisms of action remain uncharacterized.

References

1. Evangelia Kandylaki, Eleni Paflioti, Paraskevi Somalou, et al. (2026). Dietary supplementation with a novel wild-type Pediococcus acidilactici strain suppresses inflammation and modulates the gut microbiome in a mouse model of colitis. NFS Journal. https://doi.org/10.1016/j.nfs.2026.100283
2. IBD Facts and Stats – CDC. cdc.gov. https://www.cdc.gov/ibd/data-statistics/index.html
3. Jayshree Mishra, Madyson Stubbs, Longxiang Kuang, Nitza Vara, Priyam Kumar, Narendra Kumar (2022). Inflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering. Mediators of Inflammation. https://doi.org/10.1155/2022/9621668
4. You-Zuo Chen, Chieh-Ting Chen, Tsung-Wei Shih, Wei-Hsuan Hsu, Bao-Hong Lee, Tzu-Ming Pan (2025). Probiotic Potential of Pediococcus acidilactici SWP-CGPA01: Alleviating Antibiotic-Induced Diarrhea and Restoring Hippocampal BDNF. Microbiology Research. https://doi.org/10.3390/microbiolres16120261
5. Wenhui Fu, Chen Chen, Qiang Xie, Shimin Gu, Sha Tao, Wentong Xue (2022). Pediococcus acidilactici Strain Alleviates Gluten-Induced Food Allergy and Regulates Gut Microbiota in Mice. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2022.845142